Weight Management (GLP-1-led and non-GLP-1-led)
The condition: Weight gain and difficulty losing weight can have many drivers, from lifestyle and metabolic factors to hormonal shifts and underlying insulin resistance. There isn’t one right route for everyone.
What the evidence shows: GLP-1 receptor agonists are well studied for weight management when combined with clinical supervision and nutritional support. Cause-specific approaches (addressing stress, hormonal imbalance, or insulin resistance directly) are supported by a growing evidence base, though individual results vary.
How Velthera helps: After assessment, your clinician confirms whether a GLP-1-assisted pathway or a cause-specific non-GLP-1 pathway fits you better, supported by an adjuvant supplement protocol either way. See GLP-1 Therapy (link the page) and Non-GLP-1 (link the page) Therapy for how each pathway works.
Your clinician determines this at assessment, based on your health history, laboratory baseline, and goals.
There is a consistent review process with your clinician. If it is determined that a particular pathway is no longer adequate, you can be safely switched to another.
Metabolic Health & Insulin Resistance
The condition: Insulin resistance is a state where the body’s cells respond less effectively to insulin, driving fatigue, weight gain, and long-term risk of type 2 diabetes if left unaddressed.
How Velthera helps: Your protocol may combine non-GLP-1 therapy targeting insulin sensitivity directly, our metabolic optimisation & longevity supplement protocol, and – where clinically appropriate – GLP-1 therapy, all guided by baseline lab work.
What the evidence shows: Compounds such as berberine, chromium, and alpha-lipoic acid have published evidence supporting improved insulin sensitivity as part of a broader clinical plan; they are adjunctive to, not a replacement for, medical management.
Related but distinct — speak with your clinician if you have a diabetes diagnosis, since that requires closer medical oversight.
Typically yes, to confirm insulin resistance and track progress.
Hormonal Imbalance
The condition: Hormonal imbalance can show up as irregular cycles, mood changes, skin changes, or unexplained weight shifts, often linked to oestrogen-progesterone balance or adrenal-ovarian axis function.
How Velthera helps: Support may combine our peptide therapy programme with our hormonal supplement protocol, following clinical assessment.
What the evidence shows: Botanical and nutrient-based approaches, such as vitex and evening primrose oil, have evidence supporting cycle regulation and symptom relief, typically requiring several months of consistent use before effects are noticeable.
Several months is typical for hormonal protocols — your clinician will set expectations for your specific plan.
Yes, hormonal imbalance is one of our current peptide focus areas.
Perimenopause & Menopause
The condition: Perimenopause and menopause bring oestrogen decline, affecting bone density, cardiovascular risk, mood, and vasomotor symptoms like hot flushes — a transition that benefits from proactive, not just reactive, care.
How Velthera helps: Support combines our peptide therapy programme with our post-menopausal supplement protocol, tailored to your stage of the transition.
What the evidence shows: Evidence supports targeted nutrient and botanical approaches for bone health, vasomotor symptoms, and cardiovascular risk during this transition, alongside peptide-based support; this does not replace a clinical HRT assessment where that may be appropriate.
Not necessarily — some clients use both. Your clinician can discuss where each fits.
Perimenopausal changes can begin years before menopause itself, so earlier assessment is generally more useful than waiting.
Gut Health
The condition: Gut health affects far more than digestion; it influences immunity, nutrient absorption, and metabolic function and is commonly disrupted by GLP-1 therapy, antibiotics, or chronic stress.
How Velthera helps: support combines our peptide therapy programme with our gut health supplement protocol, especially relevant if you’re also on a GLP-1 pathway.
What the evidence shows: Multi-strain probiotics and mucosal-support compounds are well evidenced for microbiome balance and gut integrity, particularly as an adjunct during GLP-1 therapy, when gastric motility naturally slows.
Not necessarily — gut health support is offered on its own where clinically relevant.
Our GLP-1 adjuvant supplement protocol already includes fibre and gut-supportive ingredients; this programme goes further where indicated.